Biosciences institute aims for $300M endowment
The effort to launch the Indiana Biosciences Research Institute got $25 million from the Legislature, but the life sciences institutions backing the effort have set their funding sights much higher.
The effort to launch the Indiana Biosciences Research Institute got $25 million from the Legislature, but the life sciences institutions backing the effort have set their funding sights much higher.
Lilly will eliminate 1,624 positions from its U.S. sales force in July, according to a notice the company made to state officials. But some of those workers may be rehired by the firm.
Major drugmakers, including Indianapolis-based Eli Lilly and Co., are closely watching Pfizer Inc.’s plan to sell Viagra directly to consumers. The bold move blows up the drug industry’s distribution model.
Infuse Accelerator hopes to make early-stage investments in 12 to 15 companies a year.
The question of whether Indiana will expand Medicaid is now back in Gov. Mike Pence's hands, after lawmakers wrapped up their session without mandating he expand coverage under the federal health care law or suggesting the route he should take.
After a four-month debate, the Legislature ended pretty much where it started on a potential expansion of Medicaid: Lawmakers are letting Gov. Mike Pence go one-on-one with President Obama to see what kind of deal he can strike.
According to one estimate, the Indianapolis-based health insurer will shed $400 million in pre-tax profits by 2017.
A decision to cut state funding by 38 percent for programs that help people stop smoking and try to prevent others from starting worries those behind the state's tobacco cessation efforts.
Indiana’s county-owned hospitals have rushed to acquire nursing homes in the past two years, opening a revenue stream for both the hospitals and the long-term-care facilities. But the additional federal revenue that has driven these purchases could come under threat.
Eli Lilly and Co. is seeking to revoke a patent held by a Johnson & Johnson unit, arguing at a London court it might delay availability of a potential treatment for Alzheimer’s disease.
Joe Swedish, who took the helm of the Indianapolis-based health insurer a month ago, threw cold-water Wednesday on widespread speculation that he will lead the company through a wave of buying hospitals and medical practices.
The Indianapolis pharmaceutical company left its full-year profit forecast unchanged despite a spike in first-quarter earnings. Revenue fell short of analyst expectations.
The Indianapolis-based health insurer easily beat Wall Street’s expectations for earnings in the first quarter and revenue rose 15 percent.
A pharmacy that makes specialty medications is recalling nearly 100 compounded drugs after federal regulators found potential safety problems during an inspection.
Mercer Marketplace will offer health coverage from four companies—Aetna Inc., Cigna Corp., UnitedHealthcare and Anthem Blue Cross and Blue Shield.
Many investors expect the health care overhaul’s coverage expansions to affect WellPoint more than other insurers.
The possibility of thousands of Indiana residents becoming eligible for addiction treatment under the federal health overhaul has state officials and providers preparing for an expansion.
Proponents of a Medicaid expansion in Indiana are playing up the economic boost the state and its businesses could see from the expansion of health insurance coverage called for by President Obama’s health reform law.
Mike Ripley, a health care lobbyist for the Indiana Chamber of Commerce, talked about the business group’s views on a proposed expansion of coverage by the Indiana Medicaid program. As it stands now, the 2013 Indiana budget bill includes a plan passed by the Senate as Senate Bill 551, which would have OK’d the Pence administration to negotiate a block grant deal with the U.S. Department of Health and Human Services to expand Medicaid coverage via a program like the Healthy Indiana Plan. When that bill was altered in the House to remove the block grant concept, the Chamber dropped its support. The altered House bill is now dead, and the original Senate plan has been added to the budget bill. Its ultimate fate is still unknown
Indianapolis development officials on Wednesday will weigh the 10-year requests from the pharmaceuticals giant related to a new manufacturing plant and improvements to existing operations downtown.